TY - JOUR
T1 - Anticoagulation in patients with device-detected atrial fibrillation with and without a prior stroke or transient ischemic attack
T2 - The NOAH-AFNET 6 trial
AU - NOAH-AFNET 6 Investigators
AU - Diener, Hans Christoph
AU - Becher, Nina
AU - Sehner, Susanne
AU - Toennis, Tobias
AU - Bertaglia, Emanuele
AU - Blomström-Lundqvist, Carina
AU - Brandes, Axel
AU - Beuger, Vincent
AU - Calvert, Melanie
AU - Camm, A John
AU - Chlouverakis, Gregory
AU - Dan, Gheorge-Andrei
AU - Dichtl, Wolfgang
AU - Fierenz, Alexander
AU - Goette, Andreas
AU - de Groot, Joris R.
AU - Hermans, Astrid
AU - Lip, Gregory Y.H.
AU - Lubinski, Andrzej
AU - Marijon, Eloi
AU - Merkely, Bela
AU - Mont, Lluis
AU - Nikorowitsch, Julius
AU - Ozga, Ann-Kathrin
AU - Rajappan, Kim
AU - Sarkozy, Andrea
AU - Scherr, Daniel
AU - Schnabel, Renate B.
AU - Schotten, Ulrich
AU - Simantirakis, Emmanuel
AU - Vardas, Panos
AU - Wichterle, Daniel
AU - Zapf, Antonia
AU - Kirchhof, Paulus
PY - 2024/8/27
Y1 - 2024/8/27
N2 - BackgroundShort and rare episodes of atrial fibrillation (AF) are commonly detected using implanted devices (device‐detected AF) in patients with prior stroke or transient ischemic attack (TIA). The effectiveness and safety of oral anticoagulation in patients with prior stroke or TIA and device‐detected AF but with no ECG‐documented AF is unclear.Methods and ResultsThis prespecified analysis of the NOAH‐AFNET 6 (Non‐Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial High Rate Episodes) trial with post hoc elements assessed the effect of oral anticoagulation in patients with device‐detected AF with and without a prior stroke or TIA in the randomized, double‐blind, double‐dummy NOAH‐AFNET 6 trial. Outcomes were stroke, systemic embolism, and cardiovascular death (primary outcome) and major bleeding and death (safety outcome). A prior stroke or TIA was found in 253 patients with device‐detected AF randomized in the NOAH‐AFNET 6 (mean age, 78 years; 36.4% women). There was no treatment interaction with prior stroke or TIA for any of the primary and secondary time‐to‐event outcomes. In patients with a prior stroke or TIA, 14 out of 122 patients experienced a primary outcome event with anticoagulation (5.7% per patient‐year). Without anticoagulation, there were 16 out of 131 patients with an event (6.3% per patient‐year). The rate of stroke was lower than expected (anticoagulation: 4 out of 122 [1.6% per patient‐year]; no anticoagulation: 6 out of 131 [2.3% per patient‐year]). Numerically, there were more major bleeding events with anticoagulation in patients with prior stroke or TIA (8 out of 122 patients) than without anticoagulation (2 out of 131 patients).ConclusionsAnticoagulation appears to have ambiguous effects in patients with device‐detected AF and a prior stroke or TIA in this hypothesis‐generating analysis of the NOAH‐AFNET 6 in the absence of ECG‐documented AF, partially due to a low rate of stroke without anticoagulation.
AB - BackgroundShort and rare episodes of atrial fibrillation (AF) are commonly detected using implanted devices (device‐detected AF) in patients with prior stroke or transient ischemic attack (TIA). The effectiveness and safety of oral anticoagulation in patients with prior stroke or TIA and device‐detected AF but with no ECG‐documented AF is unclear.Methods and ResultsThis prespecified analysis of the NOAH‐AFNET 6 (Non‐Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial High Rate Episodes) trial with post hoc elements assessed the effect of oral anticoagulation in patients with device‐detected AF with and without a prior stroke or TIA in the randomized, double‐blind, double‐dummy NOAH‐AFNET 6 trial. Outcomes were stroke, systemic embolism, and cardiovascular death (primary outcome) and major bleeding and death (safety outcome). A prior stroke or TIA was found in 253 patients with device‐detected AF randomized in the NOAH‐AFNET 6 (mean age, 78 years; 36.4% women). There was no treatment interaction with prior stroke or TIA for any of the primary and secondary time‐to‐event outcomes. In patients with a prior stroke or TIA, 14 out of 122 patients experienced a primary outcome event with anticoagulation (5.7% per patient‐year). Without anticoagulation, there were 16 out of 131 patients with an event (6.3% per patient‐year). The rate of stroke was lower than expected (anticoagulation: 4 out of 122 [1.6% per patient‐year]; no anticoagulation: 6 out of 131 [2.3% per patient‐year]). Numerically, there were more major bleeding events with anticoagulation in patients with prior stroke or TIA (8 out of 122 patients) than without anticoagulation (2 out of 131 patients).ConclusionsAnticoagulation appears to have ambiguous effects in patients with device‐detected AF and a prior stroke or TIA in this hypothesis‐generating analysis of the NOAH‐AFNET 6 in the absence of ECG‐documented AF, partially due to a low rate of stroke without anticoagulation.
UR - https://www.ahajournals.org/journal/jaha
U2 - 10.1161/JAHA.124.036429
DO - 10.1161/JAHA.124.036429
M3 - Article
SN - 2047-9980
JO - Journal of the American Heart Association
JF - Journal of the American Heart Association
ER -